All Outputs (5)

FoxO3a as a positive prognostic marker and a therapeutic target in Tamoxifen-resistant breast cancer (2019)
Journal Article
Pellegrino, M., Rizza, P., Donà, A., Nigro, A., Ricci, E., Fiorillo, M., …Morelli, C. (2019). FoxO3a as a positive prognostic marker and a therapeutic target in Tamoxifen-resistant breast cancer. Cancers, 11(12), e1858. https://doi.org/10.3390/cancers11121858

Background: Resistance to endocrine treatments is a major clinical challenge in the management of estrogen receptor positive breast cancers. Although multiple mechanisms leading to endocrine resistance have been proposed, the poor outcome of this sub... Read More about FoxO3a as a positive prognostic marker and a therapeutic target in Tamoxifen-resistant breast cancer.

Thioalbamide, a thioamidated peptide from amycolatopsis alba, affects tumor growth and stemness by inducing metabolic dysfunction and oxidative stress (2019)
Journal Article
Frattaruolo, L., Fiorillo, M., Brindisi, M., Curcio, R., Dolce, V., Lacret, R., …Cappello, A. (2019). Thioalbamide, a thioamidated peptide from amycolatopsis alba, affects tumor growth and stemness by inducing metabolic dysfunction and oxidative stress. Cells, 8(11), e1408. https://doi.org/10.3390/cells8111408

Thioalbamide, a thioamidated peptide biosynthesized by Amycolatopsis alba, is a thioviridamide-like molecule, and is part of a family of natural products representing a focus of biotechnological and pharmaceutical research in recent years due to thei... Read More about Thioalbamide, a thioamidated peptide from amycolatopsis alba, affects tumor growth and stemness by inducing metabolic dysfunction and oxidative stress.

Doxycycline, Azithromycin and vitamin C (DAV) : a potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs) (2019)
Journal Article
Fiorillo, M., Tóth, F., Sotgia, F., & Lisanti, M. (2019). Doxycycline, Azithromycin and vitamin C (DAV) : a potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs). Aging, 11(8), 2202-2216. https://doi.org/10.18632/aging.101905

Here, we devised a new strategy for eradicating cancer stem cells (CSCs), via a "synthetic-metabolic" approach, involving two FDA-approved antibiotics and a dietary vitamin supplement. This approach was designed to induce a "rho-zero-like" phenotype... Read More about Doxycycline, Azithromycin and vitamin C (DAV) : a potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs).

Hallmarks of the cancer cell of origin : comparisons with "energetic" cancer stem cells (e-CSCs) (2019)
Journal Article
Sotgia, F., Fiorillo, M., & Lisanti, M. (2019). Hallmarks of the cancer cell of origin : comparisons with "energetic" cancer stem cells (e-CSCs). Aging, 11(3), 1065-1068. https://doi.org/10.18632/aging.101822

Here, we discuss the expected hallmark(s) of the cancer cell of origin and how this may be related to a new tumor cell phenotype, namely "energetic" cancer stem cells (e-CSCs). e-CSCs show many features that would be characteristic of the cancer cell... Read More about Hallmarks of the cancer cell of origin : comparisons with "energetic" cancer stem cells (e-CSCs).

“Energetic” cancer stem cells (e-CSCs) : a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy (2019)
Journal Article
Fiorillo, M., Sotgia, F., & Lisanti, M. (2019). “Energetic” cancer stem cells (e-CSCs) : a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy. Frontiers in Oncology, 8(677), https://doi.org/10.3389/fonc.2018.00677

Here, we provide the necessary evidence that mitochondrial metabolism drives the anchorage-independent proliferation of CSCs. Two human breast cancer cell lines, MCF7 [ER(+)] and MDA-MB-468 (triple-negative), were used as model systems. To directly... Read More about “Energetic” cancer stem cells (e-CSCs) : a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy.